Skip to main content

Table 4 Resistance transformation in 5 patients and the outcomes

From: Clinical characteristics and risk factors of Aeromonas bloodstream infections in patients with hematological diseases

 

Pathogen

Antibiotic treatment

Time interval

MICs (the 1st isolate-the final isolate)

Outcomes

FEP

TZP

MEM

IPM

CIP

LVX

GEN

TGC

Case 1

Aeromonas sobria

CAZ, ET, SMZ, TGC, FEP, IPM, CIP

19

< 1–64

< 4

> 16

< 1

1–>4

1–>8

> 16

NA

Death

Case 2

Aeromonas sobria

IPM, AK, SCF, MEM

2

< 1

< 4–128

< 0.25–>16

< 1–4

1

1

2

NA

Survival

Case 3

Aeromonas hydrophila

SCF, CIP, IPM, ET

7

< 1

> 128

> 16

> 16

1–>4

1

< 1

1

Survival

Case 4

Aeromonas hydrophila

MEM, ET, LVX, CRO

8

< 1

> 128

> 16

8

1–>4

1–>8

< 1

1–>8

Amputation

Case 5

Aeromonas sobria

MEM, TGC, SCF

6

2

> 128

> 16

> 16

> 4

2–>8

< 1

1–>8

Survival

  1. Bold format, the resistant transformation antibiotics
  2. MEM meropenem, IPM imipenem, CAZ ceftazidime, ET etimicin, SMZ thimethoprim-sulphamethoxazole, TGC tegacycline, SCF cefoperazone/sulbactam, CIP ciprofloxacin, LVX levofloxacin, FEP cefepime, CRO ceftriaxone, AK amikacin, GEN,gentamicin, NA not detected